NLS Pharmaceutics ( NASDAQ: NLSP ) announced that on May 22, 2024, the company received an additional staff determination letter from Nasdaq notifying the company that it did not comply with the minimum $2,500,000 stockholders' equity requirement. The company has requested a hearing before the Nasdaq Hearings Panel to appeal the Staff's delisting determination. Source: Press Release More on NLS Pharmaceutics NLS Pharmaceutics receives Nasdaq staff delisting determination Financial information for NLS Pharmaceutics.